GlassScriptPhysician profile
Glen W Berger
NPI 1285697201
$13,981.22
in general payments reported to CMS, 2019-2025
29 companies · $1,090 in 2025
The $1,090 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,322 · 2020: $4,175 · 2021: $2,503 · 2022: $1,917 · 2023: $1,613 · 2024: $1,360 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,039 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,038.85 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $4,136.26 | 2019-2020 | |
| Amgen INC. | $2,279.61 | 2019-2025 | Repatha, Repatha, Evenity |
| Biohaven Pharmaceuticals, INC. | $1,475.90 | 2021 | |
| Glaxosmithkline, LLC. | $1,177.06 | 2019-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $1,008.54 | 2019-2024 | Xarelto, Spravato |
| Abbvie INC. | $975.68 | 2021-2024 | Vraylar, Qulipta, Linzess |
| Novo Nordisk INC | $686.22 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceutical Holding Company LTD. | $315.06 | 2022 | |
| Currax Pharmaceuticals LLC | $307.15 | 2020-2025 | Contrave, Nexletol |
| Novartis Pharmaceuticals Corporation | $276.70 | 2022-2025 | |
| Exact Sciences Corporation | $215.87 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.52 | 2019-2022 | |
| Pfizer INC. | $135.91 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $135.83 | 2019-2023 | Livalo, Seglentis |
| Boston Scientific Corporation | $123.81 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $111.60 | 2021-2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $76.68 | 2019-2025 | Mounjaro, Zepbound |
| Arbor Pharmaceuticals, INC. | $68.01 | 2019-2021 | |
| Abbott Laboratories | $63.28 | 2022-2023 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $53.11 | 2019-2020 | |
| Irhythm Technologies, INC. | $34.82 | 2024 | Zio Monitor, Zio Xt Patch |
| Takeda Pharmaceuticals U.S.A., INC. | $32.88 | 2023-2024 | Trintellix |
| Esperion Therapeutics, INC. | $31.96 | 2021-2024 | Nexletol |
| Bausch Health US, LLC | $28.43 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.19 | 2020-2022 | |
| Axsome Therapeutics, INC. | $23.09 | 2023 | Auvelity |
| Vivus LLC | $18.22 | 2019 | |
| Medicure Pharma INC. | $14.00 | 2021 | |
| Merck Sharp & Dohme LLC | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.